Clinical Trials Logo

Filter by:
NCT ID: NCT05946759 Completed - Clinical trials for Breast-Conserving Surgery

Reoperation Rate in Breast-Conserving Surgery Using Confocal Histolog® Scanner for Intraoperative Margin Assessment

SHIELD
Start date: October 10, 2023
Phase: N/A
Study type: Interventional

This PMPF study is proposed to evaluate in real life the reoperation rates (ROR) of breast cancer and/or DCIS surgery when including the use of the HLS in the context of breast lumpectomy margin assessment.

NCT ID: NCT05945888 Completed - Healthy Clinical Trials

A Study in Healthy Men to Test How Different Doses of BI 3000202 Are Tolerated and How Food Influences the Amount of BI 3000202 in the Blood

Start date: July 25, 2023
Phase: Phase 1
Study type: Interventional

The single rising dose (SRD) part of the trial investigates safety, tolerability, and pharmacokinetics of BI 3000202. The food effect (FE) part is conducted to assess the effect of food on the relative bioavailability of the BI 3000202 formulation.

NCT ID: NCT05943860 Completed - Clinical trials for Diffuse Hair Loss in Females

Efficacy and Tolerability of Pantovigar® Vegan in Female Subjects With Diffuse Hair Loss

Start date: September 13, 2021
Phase: N/A
Study type: Interventional

The objective of this study is to assess the hair growth efficacy of a Food for Special Medicinal Purposes (FSMP) Pantovigar® vegan after 3 and 6 months of intake.

NCT ID: NCT05938517 Completed - Ménière's Disease Clinical Trials

Pharmacokinetic Profile of Betahistine With and Without Selegiline in Healthy Volunteers

PK-BesT
Start date: June 2, 2021
Phase: Phase 1
Study type: Interventional

The goal of this pharmakokinetic trial is to demonstrate that Betahistine serum concentration is higher after combination treatment with Betahistine and Selegiline compared to Betahistine alone. The main questions it aims to answer are: Is the plasma concentration of betahistine higher due to combination treatment with selegiline compared to betahistine monotherapy? How is the safety of the combination treatment with betahistine and selegiline, the pharmacokinetics of betahistine in different dosages in blood, and the inter-individual differences in the metabolism? Subjects satisfying all selection criteria will receive three different dosages of Betahistine alone orally in ascending order (24 mg, 48 mg, 96 mg) in the first period. In the second period, subjects received Betahistine treatment as described for first period but after pre- and continuous treatment with 5 mg/ml Selegiline orally. Plasma concentration (namely the AUC0-240min) of betahistine will be measured before and 10, 30, 60, 90, 120, 180, 240 minutes after treatment with blood examinations. Safety parameters include assessment of adverse events, ECG, vital signs, laboratory measurements including kidney and liver function, full blood count and pregnancy and drug screening test.

NCT ID: NCT05937997 Completed - Clinical trials for Lumbar Pain Syndrome

Evaluation and Timing in an ERAS-like Structured Rehabilitation Program After Lumbar Spine Surgery

Start date: December 29, 2014
Phase: N/A
Study type: Interventional

The goal of this clinical trial is to investigate the safety of early inpatient rehabilitation after lumbar spine surgery. Participants are assigned to therapy groups C (low) - A (high) intensity and receive standardized multimodal rehabilitation for 3 weeks. Groups are compared in terms of safety, disability impairment as well as pain. Timing of rehabilitation is considered.

NCT ID: NCT05936502 Completed - Clinical trials for Head and Neck Squamous Cell Carcinoma

Ascertaining the Radiologic Prognostic Importance of Extranodal Extension on Imaging (iENE) in Head and Neck Cancer

EPIC-iENE DATA
Start date: July 11, 2022
Phase:
Study type: Observational

Extranodal extension (ENE) refers to the spread of head and neck squamous cell carcinoma (HNSCC) outside the lymph nodes. It is a well-known factor that indicates a poorer prognosis and outcome for patients who have undergone surgical removal of the cancer. In such cases, it is recommended to combine chemotherapy with radiation therapy after surgery. As the number of cases of HNSCC related to the human papillomavirus (HPV) is increasing, treatment approaches have shifted towards using radiation therapy as the primary treatment method instead of surgery. This raises an important question about the significance of ENE observed through imaging tests (referred to as iENE) and its impact on the prognosis. Unfortunately, this question remains unanswered. The objective of this project is to conduct a comprehensive study across multiple medical institutions. The investigators will gather data including scan results, histopathology reports, and data from patient charts from individuals who have been treated for head and neck cancer. The aim is to analyze and correlate the findings between the pathological evidence of ENE and the imaging results, while also assessing the prognostic value of iENE. Additionally, the investigators will explore the influence of HPV status on these factors. By collecting and analyzing this data, the investigators hope to establish standardized criteria that can assist radiologists in accurately identifying ENE through imaging tests. This research is essential for enhancing our understanding of HNSCC and improving the effectiveness of diagnostic procedures and treatment planning.

NCT ID: NCT05931016 Completed - Face Mask Clinical Trials

Impact of Surgical Mask, FFP2 Mask and FFP3 Mask (With and Without Exhalation Valve) on Exercise Tolerance and Blood Gas Parameters of Patients With Known Lung Disease and Long-term Oxygen Therapy

FFP-O2
Start date: June 26, 2023
Phase:
Study type: Observational

The aim of the study is to find out how blood gas parameters change under the use of surgical mask, FFP2 masks and FFP3 masks (with and without exhalation valve) in patients with known lung disease and long-term oxygen therapy. In particular, the question arises whether patients become hypoxemic or hypercapnic by using a mask. Or whether wearing a mask increases oxygen saturation by its reservoir function.

NCT ID: NCT05918900 Completed - Malnutrition Clinical Trials

Analyses of Malnutrition Screening in Internal Medicine

AMASIN
Start date: June 5, 2023
Phase:
Study type: Observational

The goal of this observational study is to study the presence and consequences of malnutrition risk in hospitalized internal medicine patients. The main questions it aims to answer are: 1. How many patients are at risk of malnutrition at admission? 2. Is there a link between an existing malnutrition risk and nutrition therapy that the patients receive? 3. Is there a link between an existing malnutrition risk and clinical outcome (e.g. length of hospital stay, mortality, need for rehospitalization)? Participants will be screened for malnutrition risk at admission using a validated questionnaire (Nutritional Risk Screening 2002). All relevant data regarding hospital stay will be obtained from the clinical information system after discharge.

NCT ID: NCT05917912 Completed - Erythromelalgia Clinical Trials

EASE (Efficacy of ATX01 Study in Erythromelalgia)

EASE
Start date: June 14, 2023
Phase: Phase 2
Study type: Interventional

The goal of this two-center, randomized, double-blinded, parallel-group, placebo-controlled clinical study is designed to compare the efficacy of twice daily applications of ATX01 versus placebo during two consecutive 3-week treatment periods. The primary objective is the comparison between Treatments (ATX01 15% vs. Placebo) of mean pain attack intensity score assessed for the final week of each treatment period using an 11-point Numerical Pain Rating Scale (NPRS). Mean pain attack intensity is defined as the sum of the pain intensity score of each pain attack during the last 7 full days (Day 14 to Day 20) of each Treatment Period divided by the total number of erythromelalgia pain attacks during that 7-day period. Participants will apply on feet and/or hands twice a day in the morning and in the evening, approximately 12 hours apart from the morning administration for 3 consecutive weeks each and record the pain intensity of each attack that occurs.

NCT ID: NCT05917886 Completed - Anxiety Clinical Trials

Auditory Beat Stimulation and Behavioural Variant of Frontotemporal Dementia

Start date: January 1, 2021
Phase: N/A
Study type: Interventional

The goal of this study is to examine the effects of auditory beat stimulation on anxiety in patients diagnosed with bvFTD. Main aims are: - to ascertain whether anxiety in bvFTD patients can be modulated using auditory beat stimulation - to investigate patterns of anxiety and mind wandering in bvFTD patient population Patients were asked to complete a number of questionnaires relating to well-being and mind wandering, as well as to listen daily to audio files of beat stimulation.